Amylyx counters Wall Street noise, cites demand for ALS drug

Amylyx Pharma went on the offensive Tuesday to clear up confusion regarding the U.S. launch of Relyvrio (AMX0035), its recently approved drug for amyotrophic lateral sclerosis (ALS).